{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:28:46Z","timestamp":1770485326485,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T00:00:00Z","timestamp":1406937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s12185-014-1627-6","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T16:11:07Z","timestamp":1406909467000},"page":"274-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country"],"prefix":"10.1007","volume":"100","author":[{"given":"Mohammed Dhahir","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameer I.","family":"Badi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaima S. M.","family":"Al-Zebari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasir A. S.","family":"Al-Allawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,2]]},"reference":[{"key":"1627_CR1","doi-asserted-by":"crossref","unstructured":"Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. ASH hematology. 2003:132\u201352.","DOI":"10.1182\/asheducation-2003.1.132"},{"issue":"9","key":"1627_CR2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to Imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"1627_CR3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tuna S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63(4):789\u201399.","journal-title":"Blood"},{"issue":"11","key":"1627_CR4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: writing committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1627_CR5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on Imatinib treatment: the EUTOS score. Blood. 2011;118(3):686\u201392.","journal-title":"Blood"},{"issue":"1","key":"1627_CR6","doi-asserted-by":"crossref","first-page":"e20149005","DOI":"10.4084\/mjhid.2014.005","volume":"6","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Rosti G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e20149005. doi: 10.4084\/MJHID .","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1627_CR7","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Cortes JE, Kanatarjian HM. Molecular monitoring in chronic myeloid leukemia. Cancer. 2008;112:2112\u20138.","journal-title":"Cancer"},{"key":"1627_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","volume":"89","author":"WY Au","year":"2009","unstructured":"Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim D-W, et al. Chronic Myeloid Leukemia in Asia. Int J Hematol. 2009;89:14\u201323.","journal-title":"Int J Hematol"},{"key":"1627_CR9","first-page":"20","volume-title":"Harris NL","author":"JW Vardiman","year":"2001","unstructured":"Vardiman JW, Pierre R, Thiele J. Chronic myelogenous leukemia. In: Jaffe ES, editor. Harris NL. Stein H: Vardiman JW. World Health Organization classification of tumors. Pathology and genetics tumors of haemopoietic and lymphoid tissues. IARC Press; 2001. p. 20\u20136."},{"key":"1627_CR10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Cancer. 2003;98:2636\u201342.","journal-title":"Cancer"},{"key":"1627_CR11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","volume":"18","author":"J Cortes","year":"2004","unstructured":"Cortes J. Natural history and staging of chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:569\u201384.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1627_CR12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: result of phase 2 study. Blood. 2002;99:1928\u201337.","journal-title":"Blood"},{"key":"1627_CR13","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","volume":"110","author":"JM Goldman","year":"2007","unstructured":"Goldman JM. How I treat chronic myeloid leukemia in the Imatinib era. Blood. 2007;110:2828\u201337.","journal-title":"Blood"},{"key":"1627_CR14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger W, Rosti G, Andreas H, Soverini S, Jane F. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"1627_CR15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"SG O\u2019Brien","year":"2008","unstructured":"O\u2019Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with Imatinib. Blood. 2008;112:76.","journal-title":"Blood"},{"key":"1627_CR16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","volume":"57","author":"MA Champagne","year":"2011","unstructured":"Champagne MA, Fu CH, Chang M, et al. Higher dose Imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2011;57:56\u201362.","journal-title":"Pediatr Blood Cancer"},{"key":"1627_CR17","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","volume":"101","author":"JE Cortes","year":"2003","unstructured":"Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on Imatinib mesylate therapy. Blood. 2003;101:3794\u2013800.","journal-title":"Blood"},{"key":"1627_CR18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4274\/Tjh.2012.0135","volume":"30","author":"BF Matti","year":"2013","unstructured":"Matti BF, Naji AS, Alwan AF. Evaluation of the safety of Imatinib mesylate in 200 Iraqi patients with chronic myeloid leukemia in the chronic phase: single center study. Turkish J Hematol. 2013;30:387\u201393.","journal-title":"Turkish J Hematol"},{"issue":"1","key":"1627_CR19","first-page":"47","volume":"1","author":"MAR Dhahii","year":"2011","unstructured":"Dhahii MAR, Murad NS, Matti BF. Evaluation of molecular response to Imatinib in Iraqi Chronic Myeloid leukemia patients using real time\u2013Reverse Transcriptase-Polymerase Chain Reaction (RT\u2013RT-PCR)\u2014Taqman assay. J Mol Biol Res. 2011;1(1):47\u201354.","journal-title":"J Mol Biol Res"},{"issue":"19","key":"1627_CR20","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","volume":"119","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Cortes J, Nazha A, O\u2019Brien S, Quintas A, Pierce S, Garcia G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119(19):4524\u20134526.","journal-title":"Blood"},{"key":"1627_CR21","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","volume":"26","author":"H Than","year":"2012","unstructured":"Than H, Kuan L, Seow CH, Li W, John C, Chuah C. The EUTOS Score is highly predictive for clinical outcome and survival in Asian patients with early chronic phase Chronic Myeloid Leukemia treated with Imatinib. Leukemia. 2012;26:2061\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"1627_CR22","first-page":"31","volume":"42","author":"Y Bilen","year":"2012","unstructured":"Bilen Y, Erdem F. Hematologic, cytogenetic, and molecular responses to Imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey. Turk J Med Sci. 2012;42(1):31\u20138.","journal-title":"Turk J Med Sci"},{"issue":"21","key":"1627_CR23","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, et al. Frontline Imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood. 2011;117(21):5591\u20139.","journal-title":"Blood"},{"issue":"1","key":"1627_CR24","doi-asserted-by":"crossref","first-page":"e2014007","DOI":"10.4084\/mjhid.2014.007","volume":"6","author":"T Sacha","year":"2014","unstructured":"Sacha T. Imatinib in Chronic Myeloid Leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1):e2014007. doi: 10.4084\/MJHID .","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1627_CR25","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U, Paschka P, M\u00fcller M, Kreil S, et al. Response and resistance in 300 patients with BCR-ABL\u2013Positive Leukemias treated with Imatinib in a single center. Cancer. 2005;103:1659\u201369.","journal-title":"Cancer"},{"issue":"6","key":"1627_CR26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE, Talpaz M, O\u2019Brien S, et al. Staging of chronic myeloid leukemia in the Imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306\u201315.","journal-title":"Cancer"},{"key":"1627_CR27","first-page":"291","volume":"53","author":"C Deshmukh","year":"2005","unstructured":"Deshmukh C, Saikia T, Bakshi A, et al. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, nonrandomized study. J Assoc Physicians India. 2005;53:291\u20135.","journal-title":"J Assoc Physicians India"},{"key":"1627_CR28","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1627_CR29","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"1627_CR30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","volume":"95","author":"F Cervantes","year":"2010","unstructured":"Cervantes F, Lopez-Garrido P, Montero MI, et al. Early intervention during Imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica. 2010;95(8):1317\u201324.","journal-title":"Haematologica"},{"issue":"1","key":"1627_CR31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00277-010-1031-0","volume":"90","author":"H Jiang","year":"2011","unstructured":"Jiang H, Chen SS, Jiang B, Jiang Q, Qin YZ, Lai YY, et al. Seven-year response to Imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase. Ann Hematol. 2011;90(1):41\u20136.","journal-title":"Ann Hematol"},{"key":"1627_CR32","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard dose Imatinib therapy. Blood. 2009;113:6315\u201321.","journal-title":"Blood"},{"issue":"4","key":"1627_CR33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"H Kantarjian","year":"2011","unstructured":"Kantarjian H, Giles F, Bhalla K, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after Imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141\u20135.","journal-title":"Blood"},{"key":"1627_CR34","first-page":"432","volume":"38","author":"S Young Choi","year":"2013","unstructured":"Young Choi S, Eun Lee S, Jeong Oh Y, Hyun Kim S, Woodman R, Szczudlo T, et al. Nilotinib Or High-Dose Imatinib compared with standard-dose imatinib in early chronic phase cml patients who have suboptimal molecular responses to standard-dose imatinib: including updated data from re-nice study. Blood. 2013;38:432\u201342.","journal-title":"Blood"},{"issue":"2","key":"1627_CR35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12288-011-0108-9","volume":"28","author":"S Dasgupta","year":"2012","unstructured":"Dasgupta S, Mukhopadhyay A, Mukhopadhyay S, Sarkar S, Gharami F, Koner K, Basak J, et al. Imatinib Mesylate Therapy in patients of Chronic Myeloid Leukemia with Philadelphia Chromosome Positive. An experience from Eastern India. Indian J Hematol Blood Transfus. 2012;28(2):82\u20138.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"1627_CR36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0609.2011.01637.x","volume":"87","author":"E Faber","year":"2011","unstructured":"Faber E, Muzik J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2002\u2014a report from the population-based CAMELIA registry. Eur J Haematol. 2011;87(2):157\u201368.","journal-title":"Eur J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1627-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1627-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1627-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T21:04:45Z","timestamp":1598130285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1627-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1627"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1627-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,2]]}}}